**Cerevel Study**

This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled 12 week trial to evaluate the safety and tolerability of two fixed doses of an experimental drug known as CVL-871 in male and female subjects aged 50-85 years who have dementia related apathy. During the treatment period, subjects will be randomly assigned at a 1:1:1 ratio to one of three study arms: CVL-871 1.0mg daily, CVL-871 3.0mg daily, or placebo. This trial will aim to enroll 75 participants from research sites across the United States.

**Category:** Alzheimer’s Disease Research

**Study Population:** Adults with apathy associated with dementia of the Alzheimer’s, Frontotemporal, Vascular, and/or Lewy Body type.

**Study Length:** The trial will include a 30-day screening period, a 12-week placebo-controlled treatment period, and a 4-week safety follow-up period. Each subject will participate in the trial for up to approximately 20 weeks.

**Requirements:**

* Adults 50-85 years old
* Volunteers must have mild to moderate cognitive impairment and meet criteria for probable diagnosis of one or more of the following: Alzheimer’s disease dementia (AD), frontotemporal dementia (FTD), vascular dementia (VAD), dementia with Lewy Bodies (DLB).
* Volunteers must meet criteria for clinically significant apathy in neurocognitive disorders
* A reliable caregiver who is willing to participate in the trial and spends > 10 hrs/wk with the potential subject, supervises his/her care, & will accompany subject to trial visits is required.
* Must sign an informed consent document indicating that he or she understands the purpose of the study, procedures required, and is willing to participate in the study. A legally authorized representative will be required to sign on the patient’s behalf if the subject is determined to not possess decision capacity.

**Benefits:**

Participation in this study may help to improve your symptoms of apathy associated with mild to moderate dementia, but it is also possible that your condition may not improve or may worsen. Participants have the benefit of additional health monitoring and follow up beyond what may be available as standard of care. The information we get from this study will help us understand more about the use of CVL-871 in individuals with dementia-related apathy and may help in treating this population more effectively in the future.

**Contact Information:**

Allison Acree, Lead Recruitment Coordinator – (843) 608-1950 xt.1109

Codi Cammer, Recruitment Coordinator – (843) 608-1950 xt.1110

Dr. Jacobo Mintzer, Principal Investigator – (843) 608-1950 xt.1101